A global consortium of scientists from federal laboratories, research institutes, academia, and industry has formed to address the challenges of building large-scale artificial intelligence (AI) systems and advancing trustworthy and reliable AI for scientific discovery.
The Trillion Parameter Consortium (TPC) brings together teams of researchers engaged in creating large-scale generative AI models to address...
Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, announced that they have updated the focus of their research collaboration to precision oncology.
The oncology-focused collaboration will leverage Bayer’s small molecule compound library and expertise in biology and medicinal chemistry as well...
Certis Oncology Solutions (Certis), a translational science and precision oncology company, announced it has been selected as "Overall Immunology Company of the Year" in the third annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and...
Investment supported by additional financing from a strong syndicate of new and existing institutional investors, along with industry leaders
Terray Therapeutics, a biotechnology company integrating scale experimentation and generative AI to improve the speed, cost, and success rate of small molecule drug discovery and development, announced an equity investment by...
Osmo, a machine olfaction startup, announced the receipt of a $3.5 million grant from the Bill & Melinda Gates Foundation to advance the company's AI-enabled scent platform for discovering and producing compounds that repel, attract, or destroy disease-carrying insects to improve animal and human health. The grant is in addition to...
Alimentiv Inc., AcelaBio Inc. and PharmaNest Inc. announce a collaboration to provide precision medicine and artificial intelligence (AI)-powered digital pathology solutions for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH). This collaboration will enable clinical trial sponsors to quantify the histological effects of drugs and gain deeper insights...
bit.bio, the company coding human cells for novel cures, announced its cell therapy pipeline and declared its lead cell therapy candidate as it prepares to enter clinical development in 2025. The company also announced three key additions to its Scientific Advisory Board (SAB).
bit.bio’s lead cell therapy candidate (bbHEP01) is in development as...
To help life sciences companies create sustainable value and drive growth, Accenture and Salesforce are investing in the development of Salesforce Life Sciences Cloud including new innovations, assets and accelerators, powered by data and artificial intelligence (AI).
Building on the recently announced Accenture and Salesforce generative AI collaboration, the companies will leverage...
Automation combined with on-line monitoring during the cell expansion step can bring cell therapy manufacturing efficiencies and enable increased patient accessibility and safety
908 Devices Inc., a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, and medical technology company Terumo Blood and Cell Technologies (Terumo BCT) announce a...
Telesis Bio Inc., a leader in automated multi-omic and synthetic biology solutions, announced the commercial release of its BioXp® De novo Cloning and Amplification kit on the BioXp 3250 and BioXp 9600 systems. This cell-free DNA amplification kit provides an efficient automated solution for building and amplifying DNA constructs...
